FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to obstetrics, and can be used for prediction of severe preeclampsia. Anamnestic parameters are collected and blood is analyzed. Data collection is carried out in the first trimester of pregnancy, presence of heredity weighed down by cardiovascular pathology is determined, presence of anemia is determined, creatinine, AST, PAPP-A values are evaluated, APTT and INR are determined by coagulogram. A prognostic index PIPE is calculated by formula: PIPE= -2.42X1-3.17X2+1.48X3+0.1X4-0.1X5-7.35X6+1.93X7-32.3, where PIPE is a prognostic index of developing severe preeclampsia; X1 - presence of anemia (1 - the patient has anemia (hemoglobin in 1 trimester <110 g/l), 0 - no anemia); X2 - heredity, burdened by cardiovascular pathology (1 - burdened heredity, 0 - non-aggravated heredity); X3 - level of APTT in 1 trimester, s; X4 - level of AST in 1 trimester, unit/l; X5 - level of creatinine in 1 trimester, mcmol/l; X6 - INR in 1 trimester, conv. units; X7 - level of PAPP-A in 11-13.6 weeks, MoM; Constant = - 32.3. If PIPE>0, the low risk of developing severe preeclampsia is predicted, while the PIPE≤0 high risk of developing severe preeclampsia is stated.
EFFECT: method enables predicting severe preeclampsia (early or late) with a high degree of reliability ensured by an integrated assessment of the following: anamnesis data, biochemical blood analysis and analysis of coagulogram of pregnant women with subsequent calculation of prognostic index.
1 cl, 1 tbl, 2 ex, 1 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREDICTING THE DEVELOPMENT OF HYPERTENSIVE DISORDERS DURING PREGNANCY IN THE MIDDLE RISK GROUP AMONG THE WOMEN WHO UNDERWENT COMBINED SCREENING OF THE 1ST TRIMESTER | 2023 |
|
RU2803010C1 |
METHOD OF PREDICTING THE RISK OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH TYPE 2 DIABETES MELLITUS | 2022 |
|
RU2800716C1 |
METHOD OF PREDICTING THE RISK OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH TYPE 1 DIABETES MELLITUS | 2022 |
|
RU2800717C1 |
METHOD FOR PREDICTION OF RISK OF DEVELOPING PREECLAMPSIA | 2023 |
|
RU2817206C1 |
METHOD FOR PREDICTING THE RECURRENCE OF EARLY PREECLAMPSIA BY MARKERS OF ENDOTHELIAL DYSFUNCTION | 2022 |
|
RU2795090C1 |
PREDICTION OF PREECLAMPSIA BASED ON DETERMINING EXTRACELLULAR FETAL DNA IN MATERNAL BLOOD WHEN SCREENING THE FIRST TRIMESTER OF PREGNANCY | 2019 |
|
RU2697845C1 |
METHOD FOR PREDICTION OF RISK OF DEVELOPING PREECLAMPSIA (PE) IN FIRST TRIMESTER OF PREGNANCY | 2024 |
|
RU2821130C1 |
METHOD FOR PREDICTION OF DEVELOPMENT OF PREECLAMPSIA IN WOMEN WITH REACTIVATION OF LATENT CYTOMEGALOVIRUS INFECTION IN THE SECOND TRIMESTER OF PREGNANCY | 2021 |
|
RU2765541C1 |
METHOD FOR EVALUATING RISK OF PREGNANCY FAILURE | 2012 |
|
RU2586412C2 |
METHOD FOR PREDICTING THE RISK OF DEVELOPMENT OF PRE-ECLAMPSIA IN WOMEN OF DIFFERENT SOMATOTYPES | 2018 |
|
RU2679111C1 |
Authors
Dates
2020-12-28—Published
2020-07-03—Filed